HC Wainwright Has Positive Forecast for CASI Q2 Earnings

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) – Equities research analysts at HC Wainwright raised their Q2 2025 earnings estimates for shares of CASI Pharmaceuticals in a note issued to investors on Monday, May 19th. HC Wainwright analyst S. Lee now expects that the biotechnology company will post earnings of ($0.47) per share for the quarter, up from their previous forecast of ($0.60). HC Wainwright currently has a “Buy” rating and a $4.00 target price on the stock. HC Wainwright also issued estimates for CASI Pharmaceuticals’ Q3 2025 earnings at ($0.51) EPS, Q4 2025 earnings at ($0.41) EPS, FY2026 earnings at ($1.63) EPS, FY2027 earnings at ($1.59) EPS, FY2028 earnings at ($1.57) EPS and FY2029 earnings at ($1.18) EPS.

Separately, StockNews.com initiated coverage on shares of CASI Pharmaceuticals in a research report on Thursday. They set a “hold” rating for the company.

CASI Pharmaceuticals Stock Up 2.7%

Shares of NASDAQ:CASI opened at $1.92 on Wednesday. CASI Pharmaceuticals has a one year low of $1.64 and a one year high of $7.67. The company has a 50 day moving average of $2.03 and a 200-day moving average of $2.80. The company has a debt-to-equity ratio of 1.38, a current ratio of 3.20 and a quick ratio of 2.32. The stock has a market cap of $23.61 million, a price-to-earnings ratio of -0.86 and a beta of 0.81.

CASI Pharmaceuticals (NASDAQ:CASI) last issued its quarterly earnings results on Friday, May 16th. The biotechnology company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.61) by ($0.08). CASI Pharmaceuticals had a negative return on equity of 181.52% and a negative net margin of 143.18%. The business had revenue of $6.24 million for the quarter, compared to analyst estimates of $7.39 million.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in CASI Pharmaceuticals stock. Foresite Capital Management VI LLC purchased a new stake in CASI Pharmaceuticals, Inc. (NASDAQ:CASI) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 1,329,383 shares of the biotechnology company’s stock, valued at approximately $3,762,000. CASI Pharmaceuticals makes up about 1.7% of Foresite Capital Management VI LLC’s holdings, making the stock its 13th biggest position. Foresite Capital Management VI LLC owned about 8.58% of CASI Pharmaceuticals at the end of the most recent reporting period. Institutional investors own 22.23% of the company’s stock.

CASI Pharmaceuticals Company Profile

CASI Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma.